Moores Cancer Center at University of California, San Diego (UCSD) Health has emerged as one of the leading trial sites for the Pancreatic Cancer Action Network’s (PanCAN) newly formed “Precision Promise”, the first large-scale precision medicine trial designed to offer a heretofore not possible opportunity for pancreatic cancer patients. Importantly, when it comes to this deadly disease, options are few. In fact, clinical trials are part of the care pathway bringing whole new meaning to the clinical research as a care option.
A Deadly Condition
With just a five-year survival rate of only 10%, few treatments are available for the pancreatic cancer patient and the National Comprehensive Cancer Network’s guidelines place clinical trials as the top option. But first, few people even know where to start if a loved one is diagnosed with this disease.
The Precision Promise Study
Aaron Miller, MD, PhD, and medical oncologist with UCSD, reports, “This clinical trial is different from standard clinical trials in that it has an adaptive design, meaning if a drug is not working, it can be pulled from the trial and another treatment can take its place. And if a drug is working, it can move more quickly through the trial and to the FDA for potential approval.”
As reported recently by Jackie Carr writing for UCSD Newsroom, this recently launched study counts only 15 trial site centers, including UCSD Moores Cancer Center.
Each patient enrolled in a Precision Promise trial undergoes advanced molecular profiling and receives state-of-the-art supportive care during their treatment. Precision Promise is currently open at Moores Cancer Center, the only NCI-designated comprehensive cancer center in San Diego. Patients with metastatic pancreatic cancer who have not yet had treatment, or who have received only first-line treatment, may be eligible to enroll in PanCAN’s Precision Promise.
This Precision Promise study (NCT04229004), a multi-center, seamless Phase 2/3 platform trial evaluates multiple regimens in metastatic pancreatic cancer. The primary objective here is to compare each investigational arm versus the standard of care (SOC) for superiority in overall survival in 1st and /or 2nd line metastatic pancreatic cancer patients and ultimately, determine if any patients benefit from one of the investigational arms.
The study started early 2020 and runs all the way till February 2024. Sponsored by the Pancreatic Cancer Network, the study’s secondary objectives include 1) determine short and long term safety signals of each investigational arm in pancreatic cancer patients vs. SOC; 2) determine progression-free survival (PFS) for each investigational arm vs. SOC; 3) identify rates of overall response; and 4) determine rate of clinical benefit as well as duration of clinical benefit.
The network of Precision Promise sites allows researchers at all 15 clinical trial sites to evaluate the success of all patients as they progress through treatment. Tissue samples will be collected on each patient, which may help researchers better understand why some patients respond better to specific treatments and not others.
|Research Site||Location||Principal Investigator|
|University of California, San Diego (UCSD) – Moores Cancer Center||San Diego, CA||Aaron Miller|
|Cedars-Sinai Medical Center||Los Angeles, CA||Andrew Hendifar|
|University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center||San Francisco, CA||Andrew Ko|
|University of Florida College of Medicine||Gainesville, FL||Thomas J. George|
|University of Chicago Medical Center||Chicago, IL||Hedy Kindler|
|Johns Hopkins Medicine—The Sidney Kimmel Comprehensive Cancer Center||Baltimore, MD||Daniel Laheru|
|Dana-Farber Cancer Institute||Boston, MS||Brian Wolin|
|Siteman Cancer Center, Washington University Medical Campus||St. Louis, MO||Kian Lim|
|New York University Langone Medical Center—Perlmutter Cancer Center||New York, NY||Diane Simeone|
|Evelyn H. Lauder Breast Center – Memorial Sloan Kettering Cancer Center||New York, NY||Anna Varghese|
|Weill Cornell Physicians – Solid Tumor/Gastrointestinal Oncology||New York, NY||Manuel Hidalgo Medina|
|University of Pennsylvania – Abramson Cancer Center||Philadelphia, PA||Gregory Beatty|
|The University of Texas MD Anderson Cancer Center||Houston, TX||Shubham Pant|
|Virginia Mason Hospital & Seattle Medical Center||Seattle, WA||Vincent Picozzi|
|Fred Hutchinson Cancer Research Center||Seattle, WA||Andrew Coveler|
Moores PI Point of View
Andrew Lowry, MD, chief of the Division of Surgical Oncology at Moores Cancer Center at UC San Diego Health, reported, “Precision Promise is a clinical trial that will provide patients with access to therapies rooted in science.” He continued, “Every possible patient with pancreatic cancer should be enrolled in a clinical trial because standard treatments are not enough. Precision Promise will offer options for patients with advanced pancreatic cancer including those who are untreated and those who have received prior therapies.”
Call to Action: PanCAN is a great resource for those that have a loved one diagnosed with pancreatic cancer. TrialSite is here for you as well. Join our Community, and receive tailored, unbiased news and information about research.